Search research articles
Contact Us
Filters
Showing results (91-100 of 100) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 100 results.
Archives of Gynecology and Obstetrics
|
June 10, 2017
Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey
Evelyn Klein, Matthias W Beckmann, Werner Bader, et al.
American Journal of Obstetrics and Gynecology
|
January 16, 2021
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group
Linn Woelber, Katharina Prieske, Christine Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde
|
May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus
Dominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
Cancers
|
January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Linn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Gynecologic Oncology
|
July 16, 2025
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study
Anna Jaeger, Monika Hampl, Katharina Prieske, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)
Eva Roser, Philipp Harter, Dario Zocholl, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
Peter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde
|
May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
International Journal of Cancer
|
July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Milena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 100) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 100 results.
Archives of Gynecology and Obstetrics
|
June 10, 2017
Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey
Evelyn Klein, Matthias W Beckmann, Werner Bader, et al.
American Journal of Obstetrics and Gynecology
|
January 16, 2021
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group
Linn Woelber, Katharina Prieske, Christine Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde
|
May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus
Dominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
Cancers
|
January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Linn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Gynecologic Oncology
|
July 16, 2025
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study
Anna Jaeger, Monika Hampl, Katharina Prieske, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)
Eva Roser, Philipp Harter, Dario Zocholl, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
Peter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde
|
May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
International Journal of Cancer
|
July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Milena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
Page
of 10